$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
2 Unstoppable Stocks That Could Make You Richer in 2023 and Beyond
01:45pm, Friday, 02'nd Dec 2022 The Motley Fool
It would take a lot to throw these leaders off their game.
2 Healthcare Stocks That Could Help Your Portfolio
01:07pm, Friday, 02'nd Dec 2022 The Motley Fool
These two companies have each delivered market-topping total returns over the last 10 years.
Pharma Stock Roundup: PFE & AZN Ink New M&A Deals, LLY Meets Alzheimer's Study Goal
12:55pm, Friday, 02'nd Dec 2022 Zacks Investment Research
Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.
Chinese cities announce further easing of COVID curbs, though police are still patrolling streets to stop protests
11:28am, Friday, 02'nd Dec 2022 MarketWatch
Major Chinese cities are further easing COVID restrictions, though police continue to patrol streets to avert protests.
Nasdaq, S&P 500 Futures Nervously Flit Around Ahead Of November Payrolls Data: Will Numbers Support Market Expectations For Slower Rate Hikes?
11:09am, Friday, 02'nd Dec 2022 Benzinga
US stocks are on track for a nervous start on Friday as traders look ahead to the November non-farm payrolls report for trading cues. With the Federal Reserve signaling its intention to potentially pi
2 Unstoppable Stocks That Could Make You Richer in 2023 and Beyond
08:45am, Friday, 02'nd Dec 2022
It would take a lot to throw these leaders off their game.
FDA pulls Covid antibody treatment because it's not effective against dominant omicron variants
04:32pm, Thursday, 01'st Dec 2022
The FDA said bebtelovimab is no longer authorized for use because it is not expected to neutralize the omicron BQ.1 and BQ.1.1 subvariants.
Why Is Lilly (LLY) Up 4.5% Since Last Earnings Report?
04:31pm, Thursday, 01'st Dec 2022 Zacks Investment Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Lilly's (LLY) Donanemab Betters Biogen's Alzheimer's Drug
01:09pm, Thursday, 01'st Dec 2022 Zacks Investment Research
Data from a phase III early symptomatic Alzheimer's disease study shows that Eli Lilly's (LLY) donanemab leads to a significant reduction of amyloid buildup in the brain and P-tau in the blood after s
Lilly's (LLY) Donanemab Betters Biogen's Alzheimer's Drug
09:47am, Thursday, 01'st Dec 2022
Data from a phase III early symptomatic Alzheimer's disease study shows that Eli Lilly's (LLY) donanemab leads to a significant reduction of amyloid buildup in the brain and P-tau in the blood after s
Amgen Is The Underdog In Obesity Treatment — But It's Creeping Up On Novo Nordisk, Eli Lilly
09:30am, Thursday, 01'st Dec 2022
Amgen stock could get a fresh boost Thursday after the company unveiled promising results for its obesity treatment. The post Amgen Is The Underdog In Obesity Treatment — But It's Creeping Up On Nov
Lilly said its Alzheimer's drug clears more amyloid plaque than Aduhelm
08:05am, Thursday, 01'st Dec 2022
Eli Lilly & Co. LLY, +1.96% said Wednesday night that its experimental Alzheimer's treatment did a better job at clearing amyloid plaque than Eisai and Biogen's Aduhelm in a Phase 3 clinical trial. Am
What to know about the Alzheimer’s drug data coming out this week
07:15pm, Wednesday, 30'th Nov 2022 MarketWatch
Eisai plans to share additional data about the Alzheimer’s disease treatment it's developing with Biogen this week.
Gurus Prescribed These Health Care Stocks in the 3rd Quarter
05:31pm, Wednesday, 30'th Nov 2022
Amid rising concerns about the state of the global economy, rising inflation, central bank interest rate hikes and increased Covid-19 restrictions in China, marked indexes were mixed on Wednesday morn
Eli Lilly and Company (LLY) Management Presents at 5th Annual Evercore ISI HealthCONx Conference 2022 Conference Call Transcript
05:01pm, Wednesday, 30'th Nov 2022
Eli Lilly and Company (NYSE:LLY ) 5th Annual Evercore ISI HealthCONx Conference 2022 Conference Call November 30, 2022 12:10 PM ET Company Participants Jacob Van Naarden - Executive Vice President and
Sign In
Buy LLY